Literature DB >> 19758133

Correlation between clinical activity and serological markers in a wide cohort of patients with systemic lupus erythematosus: an eight-year prospective study.

Neifred Villegas-Zambrano1, Victor M Martínez-Taboada, Ainhoa Bolívar, María San Martín, Lorena Alvarez, María José Marín, Marcos López-Hoyos.   

Abstract

Titers of serum anti-double-stranded DNA antibodies (anti-dsDNA Abs) and C3 and C4 are used for monitoring systematic lupus erythematosus (SLE) patients. Here, we assessed the relationship between the clinical activity index (SLEDAI) and serum titers of anti-dsDNA Abs, C3, and C4 in an 8-year prospective study conducted in 194 SLE patients. The association of anti-dsDNA Abs and complement with M-SLEDAI was significant but low. Ninety-eight of the 194 patients were selected because they were followed for at least 5 years. We observed four types of clinical-serological patterns: parallelism between serum and clinical activity (n = 24), clinical quiescence with partial serum activity (n = 30), clinical quiescence but serologically fully active (n = 18), and clinical activity but serologically quiescent (n = 21). The serological markers evaluated are of limited utility in the monitoring of SLE patients and their use must be individualized.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19758133     DOI: 10.1111/j.1749-6632.2009.04650.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

Review 1.  The deleterious role of basophils in systemic lupus erythematosus.

Authors:  Christophe Pellefigues; Nicolas Charles
Journal:  Curr Opin Immunol       Date:  2013-10-24       Impact factor: 7.486

2.  Immunoserological parameters in SLE: high-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activity.

Authors:  Sladjana Andrejevic; Ivica Jeremic; Mirjana Sefik-Bukilica; Milos Nikolic; Biljana Stojimirovic; Branka Bonaci-Nikolic
Journal:  Clin Rheumatol       Date:  2013-07-16       Impact factor: 2.980

3.  Pathways of impending disease flare in African-American systemic lupus erythematosus patients.

Authors:  Melissa E Munroe; Evan S Vista; Joan T Merrill; Joel M Guthridge; Virginia C Roberts; Judith A James
Journal:  J Autoimmun       Date:  2017-02-02       Impact factor: 7.094

4.  Serum protein profiling of systemic lupus erythematosus and systemic sclerosis using recombinant antibody microarrays.

Authors:  Anders Carlsson; Dirk M Wuttge; Johan Ingvarsson; Anders A Bengtsson; Gunnar Sturfelt; Carl A K Borrebaeck; Christer Wingren
Journal:  Mol Cell Proteomics       Date:  2011-02-24       Impact factor: 5.911

5.  T cell subsets and immunoglobulin G levels are associated with the infection status of systemic lupus erythematosus patients.

Authors:  Lifen Wu; Xinru Wang; Fenghua Chen; Xing Lv; Wenwen Sun; Ying Guo; Hou Hou; Haiyan Ji; Wei Wei; Lu Gong
Journal:  Braz J Med Biol Res       Date:  2017-12-11       Impact factor: 2.590

6.  Prevalence of antinuclear antibodies in inflammatory bowel disease and seroconversion after biological therapy.

Authors:  María José García; Juan Carlos Rodríguez-Duque; Marta Pascual; Coral Rivas; Beatriz Castro; Sandra Raso; Marcos López-Hoyos; María Teresa Arias-Loste; Montserrat Rivero
Journal:  Therap Adv Gastroenterol       Date:  2022-03-02       Impact factor: 4.409

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.